PTC Therapeutics, Inc. – NASDAQ:PTCT
Founder-led company
PTC Therapeutics stock price today
$49.11
+3.88
+8.58%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
PTC Therapeutics stock price monthly change
+35.95%
month
PTC Therapeutics stock price quarterly change
+35.95%
quarter
PTC Therapeutics stock price yearly change
+54.00%
year
PTC Therapeutics key metrics
Market Cap | 3.47B |
Enterprise value | 3.90B |
P/E | -6.05 |
EV/Sales | 5.58 |
EV/EBITDA | -12.55 |
Price/Sales | 4.97 |
Price/Book | -10.02 |
PEG ratio | 0.83 |
EPS | -7.68 |
Revenue | 927.55M |
EBITDA | -92.65M |
Income | -579.22M |
Revenue Q/Q | -4.65% |
Revenue Y/Y | 20.39% |
Profit margin | -80% |
Oper. margin | -64.03% |
Gross margin | 93.61% |
EBIT margin | -64.03% |
EBITDA margin | -9.99% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePTC Therapeutics stock price history
PTC Therapeutics stock forecast
PTC Therapeutics financial statements
Average Price Target
$48
Potential downside: -2.26%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 213.80M | -198.88M | -93.02% |
|---|---|---|---|
| Sep 2023 | 196.57M | -132.97M | -67.64% |
| Dec 2023 | 307.05M | -155.79M | -50.74% |
| Mar 2024 | 210.11M | -91.57M | -43.58% |
| Jun 2023 | 1338124000 | 1.91B | 143.29% |
|---|---|---|---|
| Sep 2023 | 1259885000 | 1.93B | 153.24% |
| Dec 2023 | 1903181000 | 2.72B | 143.01% |
| Mar 2024 | 1789629000 | 2.68B | 149.95% |
| Jun 2023 | -14.12M | -23.75M | 18.46M |
|---|---|---|---|
| Sep 2023 | -14.51M | -29.59M | 3.36M |
| Dec 2023 | -100.28M | -94.41M | 620.48M |
| Mar 2024 | 70.76M | -114.93M | 540K |
PTC Therapeutics alternative data
| Aug 2023 | 1,402 |
|---|---|
| Sep 2023 | 1,402 |
| Oct 2023 | 1,402 |
| Nov 2023 | 1,402 |
| Dec 2023 | 1,402 |
| Jan 2024 | 1,402 |
| Feb 2024 | 1,402 |
| Mar 2024 | 988 |
| Apr 2024 | 988 |
| May 2024 | 988 |
| Jun 2024 | 988 |
| Jul 2024 | 988 |
PTC Therapeutics other data
100.00%
0.00%
of PTCT is owned by hedge funds
173
+3
73.88M
-1.43M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 46191 |
| Apr 2024 | 0 | 5981 |
| May 2024 | 0 | 20175 |
| Jul 2024 | 0 | 2269 |
| Dec 2024 | 0 | 209318 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | BOULDING MARK ELLIOTT officer: EXEC. VP.. | Common Stock | 7,720 | $33.02 | $254,914 | ||
Option | BOULDING MARK ELLIOTT officer: EXEC. VP.. | Common Stock | 1,988 | $33.02 | $65,644 | ||
Sale | BOULDING MARK ELLIOTT officer: EXEC. VP.. | Common Stock | 6,315 | $53.14 | $335,579 | ||
Option | BOULDING MARK ELLIOTT officer: EXEC. VP.. | Common Stock | 600 | $33.02 | $19,812 | ||
Sale | BOULDING MARK ELLIOTT officer: EXEC. VP.. | Common Stock | 1,900 | $53.13 | $100,947 | ||
Sale | BOULDING MARK ELLIOTT officer: EXEC. VP.. | Common Stock | 2,093 | $53.74 | $112,484 | ||
Option | BOULDING MARK ELLIOTT officer: EXEC. VP.. | Stock Option (Right to Buy) | 7,720 | $33.02 | $254,914 | ||
Option | BOULDING MARK ELLIOTT officer: EXEC. VP.. | Stock Option (Right to Buy) | 1,988 | $33.02 | $65,644 | ||
Option | BOULDING MARK ELLIOTT officer: EXEC. VP.. | Stock Option (Right to Buy) | 600 | $33.02 | $19,812 | ||
Option | ALMSTEAD NEIL GREGORY officer: CHIEF TE.. | Common Stock | 66,956 | $51 | $3,414,756 |
| Patent |
|---|
Application Filling date: 29 Nov 2021 Issue date: 18 Aug 2022 |
Application Filling date: 18 Apr 2022 Issue date: 11 Aug 2022 |
Grant Filling date: 5 Jun 2018 Issue date: 9 Aug 2022 |
Grant Filling date: 27 Jun 2018 Issue date: 26 Jul 2022 |
Grant Utility: 2-substituted amino-naphth (1,2-d) imidazol-5-one compounds of pharmaceutically acceptable salts thereof Filling date: 10 Aug 2020 Issue date: 19 Jul 2022 |
Application 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING ALPHA-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS Filling date: 25 Jan 2022 Issue date: 14 Jul 2022 |
Grant Filling date: 27 Jun 2018 Issue date: 12 Jul 2022 |
Application Filling date: 12 May 2020 Issue date: 30 Jun 2022 |
Application Filling date: 9 Mar 2020 Issue date: 16 Jun 2022 |
Application Filling date: 10 Apr 2020 Issue date: 9 Jun 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 25 Apr 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 29 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 29 Oct 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 4 Aug 2023 | Q2 2023 Earnings Call Transcript |
uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130
Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart
How To Pick Top Pharma Stocks: Novo Nordisk And More
Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed
PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts
PTC Therapeutics: Struggling Still But Potential Remains
PTC Therapeutics: Overdependence On One Asset, Poor Cash Management
ClearPoint Neuro Is A 'Buy' Based On Growing Revenues And Decreasing Cash Burn
Diving Into Dyne Therapeutics
-
What's the price of PTC Therapeutics stock today?
One share of PTC Therapeutics stock can currently be purchased for approximately $49.11.
-
When is PTC Therapeutics's next earnings date?
Unfortunately, PTC Therapeutics's (PTCT) next earnings date is currently unknown.
-
Does PTC Therapeutics pay dividends?
No, PTC Therapeutics does not pay dividends.
-
How much money does PTC Therapeutics make?
PTC Therapeutics has a market capitalization of 3.47B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 34.2% to 937.82M US dollars.
-
What is PTC Therapeutics's stock symbol?
PTC Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "PTCT".
-
What is PTC Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of PTC Therapeutics?
Shares of PTC Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are PTC Therapeutics's key executives?
PTC Therapeutics's management team includes the following people:
- Dr. Stuart W. Peltz Co-Founder, Chief Executive Officer & Executive Director(age: 65, pay: $1,700,000)
- Mr. Eric Pauwels Chief Bus. Officer(age: 63, pay: $975,140)
- Mr. Mark Elliott Boulding Executive Vice President & Chief Legal Officer(age: 64, pay: $804,350)
- Dr. Neil Almstead Chief Technical Operations Officer(age: 58, pay: $797,410)
- Ms. Emily Luisa Hill Chief Financial Officer(age: 44, pay: $782,500)
- Dr. Allan Steven Jacobson Independent Co-Founder, Chairman of Scientific Advisory Board & Director(age: 79, pay: $140,000)
-
Is PTC Therapeutics founder-led company?
Yes, PTC Therapeutics is a company led by its founders Dr. Stuart W. Peltz and Dr. Allan Steven Jacobson.
-
How many employees does PTC Therapeutics have?
As Jul 2024, PTC Therapeutics employs 988 workers.
-
When PTC Therapeutics went public?
PTC Therapeutics, Inc. is publicly traded company for more then 12 years since IPO on 20 Jun 2013.
-
What is PTC Therapeutics's official website?
The official website for PTC Therapeutics is ptcbio.com.
-
Where are PTC Therapeutics's headquarters?
PTC Therapeutics is headquartered at 100 Corporate Court, South Plainfield, NJ.
-
How can i contact PTC Therapeutics?
PTC Therapeutics's mailing address is 100 Corporate Court, South Plainfield, NJ and company can be reached via phone at +90 82227000.
-
What is PTC Therapeutics stock forecast & price target?
Based on 3 Wall Street analysts` predicted price targets for PTC Therapeutics in the last 12 months, the avarage price target is $48. The average price target represents a -2.26% change from the last price of $49.11.
PTC Therapeutics company profile:
PTC Therapeutics, Inc.
ptcbio.comExchange:
NASDAQ
Full time employees:
988
Industry:
Biotechnology
Sector:
Healthcare
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
100 Corporate Court
South Plainfield, NJ 07080
South Plainfield, NJ 07080
CIK: 0001070081
ISIN: US69366J2006
CUSIP: 69366J200
